• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

    10.90 -0.24 (-2.15%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 745,804
    Open 11.17
    Bid (Size) 10.77 (100)
    Ask (Size) 12.37 (600)
    Prev. Close 11.14
    Today's Range 10.74 - 11.60
    52wk Range 5.680 - 13.33
    Shares Outstanding 42,734,644
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +7.7%
    +7.7%
    1 Month
    -11.8%
    -11.8%
    3 Month
    +54.6%
    +54.6%
    6 Month
    +39.0%
    +39.0%
    1 Year
    -2.1%
    -2.1%

    More News

    Read More
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Which stocks are experiencing notable movement on Monday? ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗
    Via Benzinga
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan (CGEM) Q2 R&D Jumps 68% ↗
    Via The Motley Fool
    News headline image
    CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix ↗
    Via Stocktwits
    News headline image
    Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
    From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
    Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
    The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
    What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
    The current price of Cullinan Therapeutics, Inc. - Common Stock is 10.90
    When was Cullinan Therapeutics, Inc. - Common Stock last traded?
    The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
    What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
    The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 465.81M
    How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
    Cullinan Therapeutics, Inc. - Common Stock has 466M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.